Adaptive Phage Therapeutics, Inc.

45 articles about Adaptive Phage Therapeutics, Inc.

• Adaptive Phage Therapeutics to Present at the FDA and NIH Hosted Workshop on Science and Regulation of Bacteriophage Therapy

  8/24/2021

  Adaptive Phage Therapeutics, Inc. today announced that Robert Hopkins, MD, Chief Medical Officer, will present at the upcoming Science and Regulation of Bacteriophage Therapy Workshop, hosted by the U.S. Food and Drug Administration (FDA)

• 

  BioSpace Movers & Shakers, Aug. 6

  8/6/2021

  Biopharma and life sciences companies strengthen their leadership teams with these Movers & Shakers.

• Adaptive Phage Therapeutics Appoints Robert J. Hopkins, MD, MPH & TM, FACP, FIDSA, to Chief Medical Officer

  7/30/2021

  Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that it has promoted Robert Hopkins, M.D., to Chief Medical Officer.

• 

  BioSpace Movers & Shakers, July 2

  7/2/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Adaptive Phage Therapeutics Expands Board Following Series B Financing Led by Deerfield Management

  6/29/2021

  Adaptive Phage Therapeutics, Inc., a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, announced the appointment of Evan Loh, M.D., CEO of Paratek Pharmaceuticals, Inc., Jonathan Leff, Partner at Deerfield Management, and Jana Jensen, Ph.D., Chief Operating Officer at Deerfield Discovery and Development, to the company’s Board of Directors.

• Adaptive Phage Therapeutics Announces Collaboration with Oyster Point Pharma to Target Ophthalmic Diseases

  6/10/2021

  Collaboration planned to develop therapeutics potentially targeting multiple ophthalmic diseases leveraging APT’s PhageBank™ technology.

• Oyster Point Pharma Announces Collaboration with Adaptive Phage Therapeutics (APT) to Target Ophthalmic Diseases

  6/10/2021

  Oyster Point Pharma, Inc. announced a newly formed research collaboration with Adaptive Phage Therapeutics to leverage APT’s PhageBank™ technology for the development of potential treatments for multiple ophthalmic diseases.

• 

  Five Collaborations Unlocking Faster Drug Development this Week

  6/10/2021

  This week, multiple companies have partnered in attempts to bring forth new therapies. BioSpace takes a look at some of these announcements.

• Adaptive Phage Therapeutics Initiates Phase 1/2 Trial of PhageBank™ in Urinary Tract Infections

  6/3/2021

  Adaptive Phage Therapeutics Initiates Phase 1/2 Trial of PhageBank ™ in Urinary Tract Infections

• Adaptive Phage Therapeutics Announces $40.75 Million Series B Financing

  5/11/2021

  Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the company has closed a $40.75 million Series B investment round led by Deerfield Management Company.

• 

  Three Companies Land Fresh Funds to Advance Pipelines 

  5/11/2021

  2021 is shaping up to be another banner year for biotech companies as they advance the next gen technologies and therapeutics for the health of all. Here’s a few raking in cash for their programs today.

• Adaptive Phage Therapeutics Announces FDA Clearance of IND Application for PhageBank™ in Treatment of Diabetic Foot Osteomyelitis

  3/10/2021

  Adaptive Phage Therapeutics Announces FDA Clearance of IND Application for PhageBank ™ in Treatment of Diabetic Foot Osteomyelitis

• Adaptive Phage Therapeutics Announces FDA Clearance of IND Application for PhageBank™ for the Treatment of Prosthetic Joint Infections

  2/10/2021

  Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat the global rise of bacterial and viral infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PhageBank™

• Adaptive Phage Therapeutics to Participate in the NobleCon17 Virtual Investor Conference

  1/15/2021

  Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the company will participate in the 17th Annual Small & Microcap Investor Conference (NobleCon17) being organized by Noble Financial Group, taking place virtually on January 19-20, 2021.

• PhageBank™ Deployed in Texas Outbreak of Life-Threatening Carbapenem Resistant A. baumannii (CRAB) in COVID-19 Patients

  11/2/2020

  Eight COVID-19 + CRAB patients have received PhageBank™ therapy under FDA-approved emergency allowance, with more anticipated

• PhageBank™ Deployed in Texas to Save COVID-19 Patients from Life-Threatening Carbapenemase Resistant A. baumannii (CRAB) Outbreak

  10/29/2020

  Nine COVID-19 patients have received PhageBank™ therapy under FDA-approved emergency allowance, with more anticipated

• Adaptive Phage Therapeutics Receives Orphan Drug Designation for PhageBank™ in Prosthetic Joint Infections

  10/22/2020

  Adaptive Phage Therapeutics Receives Orphan Drug Designation for PhageBank ™ in Prosthetic Joint Infections

• Adaptive Phage Therapeutics Receives Department of Defense Award for Development of COVID-19 Vaccine

  8/20/2020

  Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat the global rise of bacterial and viral infectious diseases, today announced the Department of Defense (DoD) awarded APT $9.8 million for research development of multiple high-priority, bacteriophage-based display vaccine candidates against the novel coronavirus (SARS-CoV-2). The effort will advance an

• Adaptive Phage Therapeutics Announces Mayo Clinic as Lead Investor in Convertible Note Financing

  8/5/2020

  Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced Mayo Clinic has committed $1.75M as a lead investor in a $7 million convertible note financing round.

• Adaptive Phage Therapeutics Enters Agreement with Mayo Clinic to Commercialize a Phage Susceptibility Test

  6/9/2020

  Mayo Clinic and Adaptive Phage Therapeutics (APT) today announced a collaboration to advance and commercialize a phage susceptibility test (PST) linked exclusively to APT’s PhageBank™ investigational therapy. At launch, the PST will be offered as a laboratory developed test for worldwide commercial availability by Mayo Clinic Labo